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Clinical Trials
Favorable Mortality Trends for Tolvaptan: No Effect of LV Remodeling
Vasopressin stimulates fluid retention and hyponatremia through V2 receptorslocated in the collecting ducts of the kidneys. Tolvaptan is an orally available
V2-receptor antagonist. Udelson and colleagues randomized 240 stable subjects with
ejection fraction30% to either tolvaptan or placebo, in addition to standard heart
failure (HF) therapy. After 1 year, there was no significant effect on the primary study
end point of left ventricular (LV) end-diastolic volume. However, there was a statisti-
cally significant reduction for the combination of mortality or hospitalization for
congestive HF. In a well-treated population of stable HF patients, tolvaptan did not
reduce LV volumes, but did reduce mortality and HF hospitalizations. See page
2151. See figure.
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Interventional Cardiology
Elevated Fibrinogen Reduces Efficacy of Eptifibatide
Smallmolecule glycoprotein IIb/IIIa inhibitors have been shown to reduce peripro-cedural complications frompercutaneous coronary intervention, but there appears
to be individual differences in the response to these medications. Mahmud and
colleaguesmeasured platelet aggregation 10min after either a single-bolus (180g/kg)
or double-bolus of eptifibatide (EP). After the single bolus, 61% of patients did not
achieve adequate platelet inhibition (95% reduction in platelet aggregation). Using
multivariable regression, an elevated fibrinogen level was the only independent predic-
tor of an inadequate response to EP. This study suggests that measurements of
fibrinogen levels prior to use of EP may be of value to ensure adequate platelet
inhibition. See page 2163. See figure.
Vascular Risk Factors
Homocysteine Stimulates Release of CD40 From Platelets
While elevated homocysteine (Hcy) has been recognized as a cardiac risk factor,the biologic pathways remain disputed. Prontera and colleagues studied the
link between homocysteine and the CD40/CD40 ligand system in a series of experi-
ments. Patients with plasma Hcy15 mol/l had soluble CD40L concentrations 4
times higher than those with Hcy15 mol/l. When exposed to Hcy, human
umbilical vein endothelial cells produced CD40 messenger ribonucleic acid and
platelets produced soluble CD40L. This study suggests a molecular link between Hcy
and the CD40/CD40L dyad which may explain the increased risk of cardiovascular
disease in subjects with high Hcy levels. See page 2182.
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Cardiac Surgery
No Survival Benefit for Mitral Annuoplasty at Time of CABG
Many surgeons recommend concomitant mitral valve (MV) annuloplasty forpatients with moderate/severe (3/4) functional ischemic mitral regurgita-
tion (MR) who undergo coronary artery bypass grafting (CABG). Mihaljevic and
colleagues retrospectively analyzed almost 400 patients with ischemicMRwho under-
went CABG.Overall, there was little benefit toMV annuloplasty; despite its success at
eliminating MR there were no differences in symptomatic benefit or survival at
multiple time points. This study suggests that there is little long-term benefit to MV
annuloplasty for ischemic MR. See page 2191. See figure.
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Cardiac Imaging
64-Slice MSCT Can Reliably Exclude In-Stent Restenosis
Visualization of in-stent segments with computed tomography is particularlychallenging because themetallic struts result in “blooming artifacts” whichmake
them appear thicker and can obscure nearby structures. Cademartiri and colleagues
hypothesized that the improved spatial resolution of 64-slice multislice computed
tomography (MSCT)would improve diagnostic accuracy for in-stent restenosis (ISR).
They report sensitivity and specificity of 95% and 93% for detecting ISR50%with
coronary angiography as the gold standard. Importantly, a negative predictive value of
99% suggests that MSCT may be a reliable noninvasive method for excluding ISR.
See page 2204.
